Stock Taper
| DATE | TYPE | RATIO |
|---|---|---|
| 2021-10-27 | Reverse | 1:4000 |
| 2015-07-07 | Reverse | 1:20 |
| 2013-04-15 | Reverse | 1:50 |
| 2008-03-03 | Reverse | 1:250 |
BioRestorative Therapies, Inc. develops regenerative medicine products using adult stem cells for treating spine, disc, and metabolic disorders, with programs in clinical and preclinical stages.

BRTX-100 is BioRestorative Therapies' lead investigational cell therapy, using a patient's own mesenchymal stem cells injected into damaged discs to treat chronic lumbar disc disease non-surgically, recently completing Phase 2 enrollment.
| Icon | PRODUCT | Q2-2025 | Q3-2025 | Q4-2025 | Q1-2026 |
|---|---|---|---|---|---|
![]() | Product | $300K | — | $0 ▼ | $11.87K ▲ |
![]() | Royalty | $3.3K | $11.8K ▲ | $19.6K ▲ | $11.3K ▼ |
Overall rating: C+
| PEER | PRICE | |
|---|---|---|
DWTX | $2.65 | COMPARE |
EDSA | $4.62 | COMPARE |
MRKR | $1.37 | COMPARE |
COCP | $1.10 | COMPARE |
TRAW | $0.59 | COMPARE |
IMRN | $1.15 | COMPARE |
BOLT | $3.81 | COMPARE |
IMNN | $1.60 | COMPARE |